Defactinib Posters

An Alternative Splicing Signature that Identifies Breast Cancer Stem Cells

Irina M. Shapiro, Jiangwen Zhang, Alan G. Derr, Christian M. Vidal, Alissa A. Neill, Qunli Xu, Daniel W. Paterson, Jonathan A. Pachter and David T. Weaver
April 02, 2012
LB-197; American Association for Cancer Research Annual Meeting

The Wnt Inhibitor VS-507 Reduces Cancer Stem Cell Function in vitro and Tumorigenicity in Mice

Jonathan A. Pachter, Jennifer E. Ring, Vihren N. Kolev, Alissa A. Neill, Christian M. Vidal, Brian T. Sullivan, Kevin T. Sprott, Mahesh V. Padval and Qunli Xu
April 02, 2012
LB-194; American Association for Cancer Research Annual Meeting

The FAK Inhibitors VS-4718 and VS-5095 Attenuate Breast Cancer Stem Cell Function in vitro and Tumor Growth in vivo

Qunli Xu, Christian M. Vidal, Jennifer E. Ring, Vihren N. Kolev, Irina M. Shapiro, Alissa A. Neill, Kevin T. Sprott, Mitchell Keegan, Daniel W. Paterson, Mahesh V. Padval and Jonathan A. Pachter.
April 02, 2012
LB-192; American Association for Cancer Research Annual Meeting

Gene Expression and Alternative Splicing Signatures Discriminate Breast Cancer Stem Cells from Fibroblasts

David T. Weaver, Irina M. Shapiro, Alan G. Derr, Daniel W. Paterson, Jonathan A. Pachter
June 04, 2012
1057; American Society of Clinical Oncology

FAK Inhibitor VS-4718 Preferentially Attenuates Growth of Malignant Mesotheliomas with NF2 Mutation: Role of Cancer Stem Cells

Irina M. Shapiro, Vihren N. Kolev, Christian M. Vidal, Mitchell Keegan1, Qunli Xu, Craig Menges, Joseph R. Testa and Jonathan A. Pachter
September 14, 2012
P1.14; International Mesothelioma Interest Group

The Pan-PI3K/mTOR Kinase Inhibitor VS-5584 Preferentially Targets Cancer Stem Cells in Breast Cancer Models

Jonathan A. Pachter, Vihren N. Kolev, Alissa A. Neill, Quentin Wright, Mahesh V. Padval & Qunli Xu
November 09, 2012
405; 2012 EORTC/AACR Molecular Targets Meeting

The FAK Inhibitor VS-4718 Attenuates Breast Cancer Stem Cell Function and Inhibits Tumor Growth in vivo

Qunli Xu, Vihren N. Kolev, Quentin G. Wright, Christian M. Vidal, Irina M. Shapiro, Jennifer E. Ring, Mahesh V. Padval, Mitchell Keegan, and Jonathan A. Pachter
November 09, 2012
400; 2012 EORTC/AACR Molecular Targets Meeting

The Cancer Stem Cell-Targeting Wnt Inhibitor VS-507 Reduces Breast Cancer Growth and Metastasis

Jennifer E. Ring, Vihren N. Kolev, Christian M. Vidal, Irina M. Shapiro, Mahesh V. Padval, Mitchell Keegan, Jonathan A. Pachter, and Qunli Xu
December 08, 2012
P6-11-07; 2012 San Antonio Breast Cancer Symposium

FAK Inhibitor VS-4718 Attenuates Breast Cancer Stem Cell Function in vitro and in vivo

Vihren N. Kolev, Quentin G. Wright, Christian M. Vidal, Irina M. Shapiro, Mahesh V. Padval, Mitchell Keegan, Qunli Xu and Jonathan A. Pachter
December 08, 2012
P6-11-09; 2012 San Antonio Breast Cancer Symposium

Combined inhibition of PI3K isoforms and mTOR kinase is critical for cancer stem cell inhibition by VS-5584

Vihren N. Kolev, Quentin G. Wright, David T. Weaver, Jennifer E. Ring, Christian M. Vidal, Mahesh V. Padval, Jonathan A. Pachter and Qunli Xu
April 07, 2014
AACR 2014

VS6063 TNBC CSC AACR 2014

Qunli Xu, Vihren N. Kolev, Quentin G. Wright, Jennifer E. Ring, Christian M. Vidal, Irina M. Shapiro, David T. Weaver, Mahesh V. Padval and Jonathan A. Pachter
April 07, 2014
AACR 2014

VS5584 anti-tumor activity in xenograft models AACR 2014

Anthony F. Trombino, Mahesh V. Padval, Quentin F. Wright and Qunli Xu
April 07, 2014
AACR 2014

iMig 2014: COMMAND : A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Defactinib as Maintenance Therapy

Paul Baas1, Dean Fennell2, Richard J. Gralla3, Hedy Kindler4, Lee M. Krug5, Anna K. Nowak6, Lawrence H. Schwartz7, Mitchell Keegan8, Joanna C. Horobin8
October 23, 2014
iMig, Cape Town October 2014

  1. The Netherlands Cancer, Amsterdam NL; 2. University of Leicester, Leicester UK; 3. Albert Einstein College of Medicine, Bronx, NY USA; 4. University of Chicago, Chicago, IL USA; 5. Memorial Sloan-Kettering Cancer Center, New York, NY USA; 6. University of Western Australia, Perth, AU; 7. Columbia University College of Physicians and Surgeons, New York USA; 8. Verastem, Needham, MA USA
EORTC 2014: The cancer stem cell inhibitors VS-6063 (defactinib) and VS-5584 exhibit synergistic anticancer activity in preclinical models of mesothelioma

Qunli Xu1, Winnie F. Tam1, Christian M. Vidal1, Vihren N. Kolev1, Yuwaraj Kadariya2, Craig W. Menges2, Joseph R. Testa2, and Jonathan A. Pachter1
November 21, 2014
EORTC, Barcelona November 2014

1Verastem Inc., Boston, MA; 2Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, PA

EORTC 2014: PI3K/mTOR inhibitor VS-5584 targets cancer stem cells and prevents tumor regrowth after chemotherapy in preclinical models of small cell lung cancer

Vihren N. Kolev1, Mahesh V. Padval1, Quentin G.Wright1, Jill Ricono2, David T. Weaver1, Jonathan A. Pachter1, and Qunli Xu1
November 21, 2014
EORTC, Barcelona November 2014

1Verastem Inc., Boston, MA; 2Molecular Response, San Diego, CA

EORTC 2014: A first-in-Asian phase I dose escalation study to evaluate the safety and pharmacokinetics of VS-6063 (defactinib), a focal adhesion kinase inhibitor in subjects with non-hematologic malignancies

1Toshio Shimizu, MD, PhD, 2Hidemi Aida, PhD, 2Chiaki Hashii, 3Joanna Horobin, MB, ChB, 3Mitchell Keegan, PhD, 3Mahesh Padval, PhD, 3Anne Poli, 3Lindsey Wilson, 1Kazuhiko Nakagawa, MD, PhD

November 21, 2014
EORTC, Barcelona November 2014

1Phase 1 Clinical Trials Program, Department of Medical Oncology, Kinki University Faculty of Medicine, Osaka, Japan; 2Japan Clinical Research Operations (JCRO), Tokyo, Japan; 3Verastem, Inc., Boston, MA, USA

EORTC 2014: FAK Inhibitor VS-6063 (Defactinib) Targets Mesothelioma Cancer Stem Cells Which Are Enriched by Standard of Care Chemotherapy

Jonathan A. Pachter1, Vihren N. Kolev1, Laurel Schunselaar3, Irina M. Shapiro1, Raphael Bueno2, Paul Baas3, David T. Weaver1 and Qunli Xu1
November 21, 2014
EORTC, Barcelona November 2014

1Verastem Inc., Boston, MA; 2Brigham & Women’s Hospital, Boston, MA; 3Netherlands Cancer Institute, Amsterdam

ASH 2014: VS-4718, a Potent Focal Adhesion Kinase (FAK) Inhibitor, Exhibits Anticancer Activity in Leukemia Models in Vitro and in Vivo

Winnie F. Tam, PhD, Jennifer E. Ring, Anthony F. Trombino, PhD, Jonathan A. Pachter, PhD, Mahesh V. Padval, PhD, Qunli Xu, PhD, David T. Weaver, PhD

December 07, 2014
56th ASH Annual Meeting & Exposition

Verastem Inc., Boston, MA

ASH 2014: Proline-Rich Tyrosine Kinase (PYK2) Promotes Tumor Progression in Multiple Myeloma (MM) and Represents a Novel Target for Therapy in MM

Y Zhang, M Moschetta, D Huynh, YT Tai, Y Zhang, W Zhang, Y Mishima, JE. Ring, WF Tam, Q Xu, P Maiso, M Reagan, I Sahin, A Sacco, S Manier, Y Aljawai, S Glavey, NC Munshi, KC Anderson, J Pachter, AM. Roccaro, IM. Ghobrial Dana
December 07, 2014
56th ASH Annual Meeting & Exposition

Farber Cancer Institute, Department of Medical Oncology, Harvard Medical School, Boston, MA; Verastem Inc., Cambridge, MA

ASH 2014: Targeting PYK2 Mediates Microenvironment-Specific Myeloma Cell Death

Mark B. Meads1, Bin Fang2, Linda Mathews1, Jennifer Gemmer1, Liang Nong1, Ismael Rosado – Lopez1, Tuan Nguyen1, Jennifer E. Ring7, William Matsui5, A. Robert MacLeod6 , Jonathan A. Pachter7, Lori A. Hazlehurst3, John M. Koomen2,3, and Kenneth H. Shain1,4
December 07, 2014
56th ASH Annual Meeting & Exposition

Departments of Chemical Biology and Molecular Medicine 1, Proteomics 2, Molecular Oncology 3, and Malignant Hematology 4 at Moffitt Cancer Center and Research Institute, Tampa, Florida 5, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, Baltimore, Maryland 6 ISIS Pharmaceuticals, Carlsbad, California & 7 Verastem, Inc, Needham, Massachusetts

ASH 2014: PYK2 Inhibitors Sensitize Hypoxia-Induced Drug Resistant Multiple Myeloma Cell

Barbara Muz1, Maurizio Buggio1, Feda Azab1, Anthony F. Trombino2, Mahesh Padval2 and Abdel Kareem Azab1
December 08, 2014
56th ASH Annual Meeting & Exposition

1Department of Radiation Oncology, Cancer Biology Division, Washington University in Saint Louis School of Medicine, Saint Louis MO, USA; 2 Verastem, Inc., Boston MA, USA

SABCS 2014: FAK inhibitors VS-6063 (defactinib) and VS-4718 reduce cancer stem cells in models of triple negative breast cancer

Vihren N. Kolev1, Sean McDermott2, Max Wicha2, Jonathan A. Pachter1, Qunli Xu1, David T. Weaver1
December 14, 2014
San Antonio Breast Cancer Symposium

1Verastem, Inc., Boston, MA, 2University of Michigan Cancer Center, Ann Arbor, MI

AACR 2015: FAK and PI3K/mTOR Inhibitors Target Cancer Stem Cells: Implications for SCLC Treatment Strategies

Vihren N. Kolev, Qunli Xu, Mahesh Padval, Jonathan A. Pachter and David T. Weaver Verastem Inc., Boston, MA
April 20, 2015
AACR Annual Meeting 2015

AACR 2015: FAK Inhibitor VS-6063 (Defactinib) Targets Mesothelioma Cancer Stem Cells, which are Enriched by Standard of Care Chemotherapy

Jonathan A. Pachter1, Vihren N. Kolev1, Laurel Schunselaar2, Mahesh V. Padval1, Irina M. Shapiro1, Raphael Bueno3, Paul Baas2, Qunli Xu1, and David T. Weaver1
April 20, 2015
AACR Annual Meeting 2015

1Verastem Inc., Boston, MA; 2Brigham & Women’s Hospital, Boston, MA; 3Netherlands Cancer Institute, Amsterdam

WCLC 2015: VS-6063-104: A Phase 1 Dose Escalation Study of VS-5584, a Dual PI3K/mTORInhibitor …

Udai Banerji1, Dean Anthony Fennell2, Hedy Lee Kindler3, Marjorie Glass Zauderer4, Mitchell Keegan5, Lou Vaickus5
September 09, 2015
2015 IASLC World Conference on Lung Cancer

VS-6063-104: A Phase 1 Dose Escalation Study of VS-5584, a Dual PI3K/mTORInhibitor, Administered with a Fixed Dose of VS-6063, a Focal Adhesion Kinase Inhibitor, in Subjects with Relapsed Malignant Mesothelioma

1 Royal Marsden Hospital, Sutton Surrey, UK; 2 University of Leicester, Leicester, UK; 3 University of Chicago, Chicago, IL, USA; 4 Memorial Sloan-Kettering Cancer Center, New York, NY, USA; 5 Verastem Inc., Boston, MA, USA

WCLC 2015: COMMAND: A Phase 2 Randomized, Double-blind, Placebo-Controlled, Multicenter Study of Defactinib as Maintenance Therapy …

Hedy Lee Kindler1, Dean Fennell2, Paul Baas3, Marjorie Zauderer4, Anna K. Nowak5, Richard J. Gralla6, Takashi Nakano7, Marcelyne Joseney-Antoine8, Anne Poli8, Mitchell Keegan8, Lou Vaickus8
September 09, 2015
2015 World Conference on Lung Cancer

COMMAND: A Phase 2 Randomized, Double-blind, Placebo-Controlled, Multicenter Study of Defactinib as Maintenance Therapy in Subjects with Malignant Pleural Mesothelioma which has Not Progressed on at least 4 Cycles of Pemetrexed/Platinum Therapy

1 University of Chicago, Chicago, USA; 2 University of Leicester, Leicester, United Kingdom; 3 Netherlands Cancer Institute, Amsterdam, Netherlands; 4 Memorial Sloan-Kettering Cancer Center, NYC, USA; 5 University of Western Australia and Sir Charles Gairdner Hospital, Nedlands, Australia; 6 Albert Einstein College of Medicine, Jacobi Medical Center, Bronx, NY, USA; 7 Hyogo College of Medicine, Hyogo, Japan; 8 Verastem, Inc., Boston, USA

SITC 2015: FAK/PYK2 Inhibitors VS-6063 and VS-4718 Enhance Immune Checkpoint Inhibitor Efficacy

Jennifer E. Ring1, Yajuan Li1, Kam Sprott1, Irina M. Shapiro1, David DeNardo2, Yan Wang1, David T. Weaver1, and Jonathan A. Pachter1
November 05, 2015
SITC 2015

1Verastem Inc., Boston, MA; 2Washington University, St. Louis, MI

Vice President of Development, Verastem, Inc.

SITC 2015: Focal Adhesion Kinase Inhabition Enables Efficacy of Checkpoint Immunotherapy in Pancreatic Cancer

Hong Jiang1,5, Samarth Hegde1,5, Brett L. Knolhoff1,5, Yu Zhu1,5, John Herndon1,5, Esther Leu4, William Hawkins3,6, Irina M. Shapiro7, David T. Weaver7, Jonathan A. Pachter7, Andrea Wang-Gillam1,6, and David G. DeNardo1,2,5,6
November 05, 2015
SITC 2015

1Department of Medicine, 2Department of Pathology and Immunology, 3Department of Surgery, 4Division of Biostatistics, 5ICCE Institute, 6Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA
7Verastem Inc., Needham, Massachusetts 02494, USA

EORTC 2015: Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity

November 06, 2015
EORTC 2015

Alan Serrels,1,2 Tom Lund,1 Bryan Serrels,1 Adam Byron,1 Rhoanne C. McPherson,2 Alexander von Kriegsheim,1 Laura Gómez-Cuadrado,1 Marta Canel,1 Morwenna Muir,1 Jennifer E. Ring,3 Eleni Maniati,4 Andrew H Sims,1 Jonathan A. Pachter,3 Valerie G. Brunton,1 Nick Gilbert,5 Stephen M. Anderton,2 Robert J.B. Nibbs,6 and Margaret C. Frame1

EORTC 2015: Focal Adhesion Kinase Inhabition Enables Efficacy of Checkpoint Immunotherapy in Pancreatic Cancer

Hong Jiang1,5, Samarth Hegde1,5, Brett L. Knolhoff1,5, Yu Zhu1,5, John Herndon1,5, Esther Leu4, William Hawkins3,6, Irina M. Shapiro7, David T. Weaver7, Jonathan A. Pachter7, Andrea Wang-Gillam1,6, and David G. DeNardo1,2,5,6

EORTC 2015: FAK/PYK2 Inhibitors VS-6063 and VS-4718 Enhance Immune Checkpoint Inhibitor Efficacy

Jennifer E. Ring1, Yajuan Li1, Kam Sprott1, Irina M. Shapiro1, David DeNardo2, Yan Wang1, David T. Weaver1, and Jonathan A. Pachter1
November 06, 2015
EORTC 2015

1Verastem Inc., Boston, MA; 2Washington University, St. Louis, MI

EORTC 2015: FAK Inhibition Targets Cancer Stem Cells

Vihren N. Kolev, Yan Wang, Kam Sprott, Irina Shapiro, Jennifer Ring, Jonathan A. Pachter, David T. Weaver
November 06, 2015
EORTC 2015

Verastem Inc., Needham, Massachusetts 02494, USA

AACR 2016: FAK Inhibition Re-sensitizes Platinum-resistant Serous Ovarian Cancer

April 18, 2016
AACR 2016

Lisa M. Bean1*, Florian J. Sulzmaier1*, Isabelle Tancioni1, Sean Uryu1, Christine Jean1, Xiao Lei Chen1, Elizabeth G. Kleinschmidt1, Kristen M. Anderson1, Edward A. Cordasco1, Joshua Axelrod1, Vihren N. Kolev2, Jonathan A. Pachter2, Dwayne G. Stupack1 and David D. Schlaepfer1

AACR 2016: FAK/PYK2 Inhibition Enhances Immune Checkpoint Inhibitor Efficacy

April 18, 2016
AACR 2016

Yan Wang1, Jennifer E. Ring1, Kam Sprott1, David DeNardo2, David T. Weaver1 and Jonathan A. Pachter1

Although durable responses to single agent immune checkpoint inhibitors have been reported, additional approaches are needed to extend this therapeutic benefit to a greater proportion of patients. Combination of immunotherapy agents with tumor microenvironment modulators has the potential to overcome barriers that tumor cells develop to evade the immune system, and provide benefit to a greater proportion of patients. Focal Adhesion Kinase (FAK) and the family member PYK2 are potentially valuable targets due to their roles in regulating key cellular populations in the tumor microenvironment. In addition to targeting cancer stem cells, the FAK/PYK2 dual inhibitors, VS-6063 and VS- 4718, have been shown to inhibit monocyte-derived macrophages, reduce tumor-associated macrophages in xenograft models, and promote a CD8+ T cell-mediated anti-tumor response in squamous cell carcinoma models.

1 Verastem Inc., Boston, MA; 2 Washington University, St. Louis, MO

Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 in AML

December 10, 2017

Xiangmeng Wang [1], [2] , Po Yee Mak [1], Mu Hong [1], Wenjing Tao [1], Jonathan Pachter [3], David Weaver [3], Bing Xu [4], Michael Andreeff [1], Bing Z Carter [1].
[1] Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;  [2] Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, P.R.China;  [3] Verastem, Inc, Needham, MA;  [4] Department of Hematology, The first Affiliated Hospital of Xiamen University, Xiamen, P.R.China

Presenter: Xiangmeng Wang, Ph.D., MD Anderson Cancer Center
Abstract Number/Publication ID: 2653
Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II
Date and Time: Sunday, December 10, 2017 from 6:00-8:00 PM ET
Location: Georgia World Congress Center, Building A, Level 1, Hall A2

Defactinib Presentations

iMig 2014: Determination of Biomarker Response in a Phase II Window of Opportunity Study of Defactinib (VS-6063), a Focal Adhesion Kinase (FAK) Inhibitor, in Subjects with Resectable MPM

Raphael Bueno1, Ritu R Gill1, Julianne Barlow1, David M Jackman1, Beow Y Yeap1, David Weaver2, Mahesh Padval2, Rachel Sorensen2, Mitchell Keegan2
October 23, 2014
iMig, Cape Town October 2014

  1. Brigham and Women’s Hospital, Boston, MA, USA; 2. Verastem, Inc., Boston, MA, USA
iMig 2014: FAK Inhibitor VS-6063 (defactinib) Targets Mesothelioma Cancer Stem Cells which are Enriched by Standard of Care Chemotherapy

Paul Baas, Department of Thorax Oncology Netherlands Cancer Institute, Amsterdam
October 23, 2014
iMig, Cape Town October 2014

WCLC 2015: The Cancer Stem Cell Inhibitors VS-6063 and VS-5584 Exhibit Synergistic Anticancer Activity in Preclinical Models of Mesothelioma

Mitchell Keegan
September 09, 2015
2015 World Conference on Lung Cancer

Vice President of Development, Verastem, Inc.

WCLC 2015: FAK Inhibitor Defactinib (VS-6063) Targets Mesothelioma Cancer Stem Cells

Jonathan Pachter
September 09, 2015
2015 World Conference on Lung Cancer

Vice President of Research, Verastem, Inc.

WCLC 2015: Phase II Study Of Defactinib, VS-6063, a Focal Adhesion Kinase (FAK) Inhibitor, in Patients With Kras Mutant Non-Small Cell Lung Cancer (NSCLC)

David E. Gerber, D. Ross Camidge, Daniel Morgensztern, Jeremey Cetnar, Ronan J. Kelly, Suresh S. Ramalingam, David R. Spigel, Woondong Jeong, Pier Scaglioni, Marilyn Li, Mitchell Keegan, Joanna C. Horobin, Timothy F. Burns
September 09, 2015
2015 World Conference on Lung Cancer

WCLC 2015: VS-5584 [PI3K/MTOR] and VS-4718 [FAK] Block SCLC Tumor Progression and Cancer Stem Cells

David Weaver
September 09, 2015
2015 World Conference on Lung Cancer

Vice President of Translational Research, Verastem, Inc.

Keystone Symposium on Stem Cells and Cancer: Targeting Cancer Stem Cells with Selective Inhibitors of FAK and PI3K/mTOR

Jonathan Pachter, VP/Head of Research, Verastem
March 10, 2016
Keystone Symposium on Stem Cells and Cancer

iMig 2016: Phase 2 Neoadjuvant Study of VS-6063, a FAK Inhibitor, in Subjects with Surgically Resectable Malignant Pleural Mesothelioma

Raphael Bueno, M.D.
May 03, 2016
The International Mesothelioma Interest Group (iMig)

Mini Symposium 10: Novel Targets – Entering in the Clinic (Track: Early Phase Clinical Trials)

Keystone Symposium on Cancer Pathophysiology

Inhibition of FAK Exerts Anti-Leukemic Activity and Potentiates ABT-199-Induced Apoptosis in AML

Lead Author: Bing Carter, Ph.D., Associate Professor, Department of Leukemia – Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
December 04, 2016
American Society of Hematology (ASH) 2016 Annual Meeting

Location: San Diego Convention Center, Hall GH
Date and Time: Saturday, December 3, 2016, 5:30 – 7:30 pm PT

AACR 2017: Reprograming the Tumor Microenvironment to Improve Responses to Therapy

David G. DeNardo, PhD. Department of Medicine, Department of Path/Immunology
April 02, 2017
AACR 2017

Duvelisib Posters

DYNAMO: A Phase 2 Study Demonstrating the Clinical Activity of Duvelisib in Patients with Double-Refractory Small lymphocytic Lymphoma

June 26, 2017

E-Poster Presentation

Title: DYNAMO: The Clinical Activity of Duvelisib in Patients with Double-Refractory Small Lymphocytic Lymphoma in a Phase 2 Study
Abstract code: E1130
Topic: Indolent Non-Hodgkin lymphoma – Clinical
Location: e-poster screens
Date and time: Friday, June 23, 2017 from 9:30 CET to Saturday, June 24, 2017 at 19:00 CET

The Dual PI3K-δ γ Inhibitor Duvelisib Stimulates Anti-Tumor Immunity and Enhances Efficacy of Immune Checkpoint and Co-Stimulatory Antibodies in a B Cell Lymphoma Model

Jonathan Pachter, Ph.D., Verastem
December 09, 2017

Title: The Dual PI3K-δ,γ Inhibitor Duvelisib Stimulates Anti-Tumor Immunity and Enhances Efficacy of Immune Checkpoint and Co-Stimulatory Antibodies in a B Cell Lymphoma Model
Presenter: Jonathan Pachter, Ph.D., Verastem
Abstract Number/Publication ID: 1541
Session: 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Poster I
Date and Time: Saturday, December 9, 2017 from 5:30-7:30 PM ET
Location: Georgia World Congress Center, Building A, Level 1, Hall A2

In Vitro, In Vivo, and Parallel Phase I Evidence Support the Safety and Activity of Duvelisib, a PI3K δ,γ Inhibitor, in Combination with Romidepsin or Bortezomib in Relapsed/Refractory T-Cell Lymphoma

Alison J. Moskowitz MD, Raphael Koch MD, Neha Mehta-Shah MD, Patricia Myskowski MD, Meenal Kheterpal MD, Ahmet Dogan MD PhD, Theresa Davey MPAS, Natasha Galasso BA, Marzouk Evan BA, Monica Shah BA, Nivetha Ganesan BS, Lakeisha Lubin BS, Youn H. Kim MD, Michael Khodadoust MD PhD, Timothy Almazan MD, Julia Dai MD, Eric D. Jacobsen MD, David M. Weinstock MD, and Steven M. Horwitz MD
December 11, 2017
Presenter: Steven Horwitz, M.D., Memorial Sloan Kettering Cancer Center
Abstract Number/Publication ID: 819
Session: 624. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: T-Cell Lymphoma Clinical Studies; Monday, December 11, 2017 from 4:30-6:00 PM ET
Date and Time: Monday, December 11, 2017 at 5:00 PM ET
Location: Georgia World Congress Center, Building A, Level 4, Marcus Auditorium

Dual PI3K-δ,γ Inhibitor Duvelisib Reduces Immunosuppressive Tregs and Myeloid Cells, Enhancing Efficacy of Checkpoint and Co-Stimulatory Antibodies in a B Cell Lymphoma Model Lymphoma Model

Jonathan A. Pachter and David T. Weaver
January 26, 2018

Presenter: Jonathan A. Pachter and David T. Weaver
Poster: 33
Session: ASCO-SITC Clinical Immuno-Oncology Symposium
Date and Time: January 26, 2018
Location: San Francisco, California, USA

Duvelisib Presentations

Preliminary results in first-line treatment of follicular lymphoma with the oral dual PI3K-delta,gamma inhibitor, duvelisib, in combination with rituximab or obinutuzumab

Carla Casulo, M.D., Assistant Professor, Wilmot Cancer Institute, University of Rochester
December 04, 2016
American Society of Hematology (ASH) 2016 Annual Meeting

Location: San Diego Convention Center, Hall GH
Date and Time: Sunday, December 4, 2016, 6:00 – 8:00 pm PT

DYNAMO: A Phase 2 Study of Duvelisib in Patients with Refractory Indolent Non-Hodgkin Lymphoma

Ian Flinn, CB Miller, KM Ardeshna, S Tetreault, SE Assouline, PL Zinzani, J Mayer, M Merli, SD Lunin, AR Pettitt, Z Nagy, O Tournilhac, KE Abou-Nassar, M Crump, ED Jacobsen, S de Vos, P Santabarbara, W Shi, L Steelman, ND Wagner-Johnston
December 05, 2016

American Society of Hematology (ASH) 2016 Annual Meeting

Location: San Diego Convention Center, Hall GH
Date and Time: Sunday, December 5, 2016, 6:15 pm PT

Verastem to Present Long-Term Follow-Up Data from the DYNAMO™ Study at the 14th International Conference on Malignant Lymphoma

June 16, 2017

Duvelisib Monotherapy Treatment Demonstrates 47% ORR in Patients with Double-Refractory Indolent Non-Hodgkin Lymphoma

88% of Patients had a Reduction in the Size of Target Lymph Nodes

Duvelisib Remains Well-Tolerated in Long-Term Follow Up

DYNAMO: A Phase 2 Study Demonstrating the Clinical Activity of Duvelisib in Patients with Double-Refractory Follicular Lymphoma

June 26, 2017

Oral Presentation

Title: DYNAMO: A Phase 2 Study Demonstrating the Clinical Activity of Duvelisib in Patients with Double-Refractory Follicular Lymphoma
Abstract code: S777
Topic: Indolent Non-Hodgkin lymphoma – Clinical
Session title: Follicular lymphoma – Clinical
Location: Hall C
Date and time: Sunday, June 25, 2017, 8:45 – 9:00 CET

Results from the Phase 3 DUO™ Trial: A Randomized Comparison of Duvelisib Vs Ofatumumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

December 10, 2017

Title: Results from the Phase 3 DUO™ Trial: A Randomized Comparison of Duvelisib Vs Ofatumumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Presenter: Ian Flinn, M.D., Ph.D., Sarah Cannon Research Institute
Abstract Number/Publication ID: 493
Session: 642. CLL: Therapy, excluding Transplantation: Targeting MRD Negative CLL with Combinations of Novel Agents and Chemoimmunotherapy Regimens, New Treatments; Sunday, December 10, 2017 from 4:30-6:00 PM ET
Date and Time: Sunday, December 10, 2017 at 4:30 PM ET
Location: Georgia World Congress Center, Building B, Level 5, Murphy BR 3-4